{"entity":{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","aka":[],"tldr":"Alpha-9 Oncology designs bespoke molecules that deliver radioactive isotopes to cancer cells, with early human trials under way in melanoma and in breast and other solid tumours.","summary":"Alpha-9 Oncology is a clinical-stage radiopharmaceutical company with offices in Vancouver and Boston. It takes a modular approach, optimising each element of a radiotherapeutic (binder, linker, chelator and isotope) and pairing therapeutic agents with imaging companions. A9-3408, an actinium-225 radiotherapeutic targeting melanocortin 1 receptor (MC1R), began a phase 1 study in melanoma in December 2025, following the 68Ga imaging agent A9-3202 that entered the clinic in 2024. In September 2026 the company dosed the first patient in a phase 1 study of two GRPR-targeting compounds, 225Ac-A9-0642 and 177Lu-A9-0631, in breast cancer and other solid tumours, with data expected in late 2027. Alpha-9 has an actinium-225 supply agreement with ITM (April 2025). In October 2024 it closed an oversubscribed USD 175 million Series C led by Lightspeed Venture Partners and Ascenta Capital. Paul Blanchfield was appointed CEO in November 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.a9oncology.com/"},{"label":"Series C press release","url":"https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/"},{"label":"GRPR phase 1 first patient dosed","url":"https://www.a9oncology.com/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-radiotherapeutics-across-multiple-solid-tumors/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["radiopharma"],"technologies":["radioligand-therapy","targeted-alpha-therapy","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The older domain alpha9oncology.com is now parked; current site is a9oncology.com. Earlier rounds not fetched."],"hq":"Vancouver","country":"CA","companyType":"radiopharma","website":"https://www.a9oncology.com/","stage":"growth","investors":["lightspeed-venture-partners","general-catalyst","a16z-bio-health","ra-capital","frazier-life-sciences","samsara-biocapital"],"funding":[{"round":"Series C","year":2024,"amountUsd":175000000,"source":"https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/"}]},"route":"/companies/alpha-9-oncology/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"company":[{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/"},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/"},{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/"},{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/"}]}}